<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Epinastine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00751</strong>&#160; (APRD00043)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Epinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00751/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00751/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00751.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00751.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00751.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00751.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00751.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00751">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Epinastin</td><td>German</td><td>INN</td></tr><tr><td>Epinastina</td><td>Spanish</td><td>INN</td></tr><tr><td>Epinastine</td><td>French</td><td>INN</td></tr><tr><td>Epinastinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Epinastine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000961/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000961/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000961">DBSALT000961</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alegain</td><td>Kyorin Rimedio</td></tr><tr><td>Alenapion</td><td>Choseido Pharmaceutical</td></tr><tr><td>Alesion</td><td>Boehringer Ingelheim</td></tr><tr><td>Alesiotec</td><td>Nihon Yakuhin Kogyo</td></tr><tr><td>Alket</td><td>Poen</td></tr><tr><td>Allernothin</td><td>Morishita Jintan</td></tr><tr><td>Allerstin</td><td>Dong Koo</td></tr><tr><td>Alpeed</td><td>Daito</td></tr><tr><td>Aplatin</td><td>Taiyo Pharmaceutical</td></tr><tr><td>Aresten</td><td>Il Sung</td></tr><tr><td>Asmot</td><td>Tatsumi Kagaku</td></tr><tr><td>Atergit</td><td>Roemmers</td></tr><tr><td>Azusaleon</td><td>Shiono Kemikaru</td></tr><tr><td>Elestat</td><td>Allergan</td></tr><tr><td>Elpinan</td><td>Towa Yakuhin</td></tr><tr><td>Epinastine</td><td>Kotobuki Seiyaku</td></tr><tr><td>Epinazion</td><td>Medisa Shinyaku</td></tr><tr><td>Epioftal</td><td>Farmindustria</td></tr><tr><td>Flurinol</td><td>Boehringer Ingelheim</td></tr><tr><td>Helvottz</td><td>Yoshindo</td></tr><tr><td>Kai lai Zhi</td><td>Carelife Pharmaceutical Co Ltd</td></tr><tr><td>Pinasion</td><td>Taisho Yakuhin</td></tr><tr><td>Purivist</td><td>Allergan</td></tr><tr><td>Relenastine</td><td>Lansier</td></tr><tr><td>Relestat</td><td>Allergan</td></tr><tr><td>Talerc</td><td>Ach&#233;</td></tr><tr><td>Timkent</td><td>Nisshin Seiyaku</td></tr><tr><td>Yupitel</td><td>Iwaki Seiyaku</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/histamine-h1-antagonists">Histamine H1 Antagonists</a></li>
<li><a href="/mesh/histamine-antagonists">Histamine Antagonists</a></li>
<li><a href="/mesh/ophthalmics">Ophthalmics</a></li></ul></td></tr><tr><th>CAS number</th><td>80012-43-7</td></tr><tr><th>Weight</th><td>Average: 249.3104<br>Monoisotopic: 249.126597495</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>15</sub>N<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WHWZLSFABNNENI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2,4-diazatetracyclo[12.4.0.0^{2,6}.0^{7,12}]octadeca-1(14),3,7(12),8,10,15,17-heptaen-3-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzazepines</td></tr><tr><th>Subclass</th><td>Dibenzazepines</td></tr><tr><th>Direct parent</th><td>Dibenzazepines</td></tr><tr><th>Alternative parents</th><td>Azepines; Benzene and Substituted Derivatives; Guanidines; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>azepine; benzene; guanidine; tertiary amine; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dibenzazepines. These are compounds with two benzene rings connected by an azepine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of itching associated with allergic conjunctivitis.</td></tr><tr><th>Pharmacodynamics</th><td>Epinastine is an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine is indicated for the prevention of itching associated with allergic conjunctivitis. Epinastine is a topically active, direct H<sub>1</sub>-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H<sub>1</sub>-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the a1-, a2-, and 5-HT<sub>2</sub> -receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system.</td></tr><tr><th>Mechanism of action</th><td>Epinastine has a multiaction effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H<sub>2</sub>-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability of epinastine is about 40%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>64%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Mainly excreted unchanged, less than 10% metabolized.</p></td></tr><tr><th>Route of elimination</th><td>Epinastine is mainly excreted unchanged. The renal elimination is mainly via active tubular secretion.</td></tr><tr><th>Half life</th><td>12 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>56 L/hr [patients with allergic conjunctivitis receiving one drop of ELESTAT&#174; ophthalmic solution in each eye twice daily for seven days]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9923</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9787</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5766</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5665</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8193</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5736</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7994</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8676</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5422</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5686</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9243</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5228</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8702</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6566</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.726</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5689
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9144
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7509 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9353
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8419
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Allergan inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.allergan.com">Allergan Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution / drops</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>